A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?
Ali Salavati, Mehmet Gencturk, Yasemin Koksel, Allyssa N. Schik, Peter R. Carroll, Felix Y. Feng, Steven P. Rowe, Courtney Lawhn-Heath, Thomas A. Hope, Jerry W. Froelich
Dive into the research topics of 'A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?'. Together they form a unique fingerprint.